ABSTRACT Objective Plasma fibrinogen is essential in thrombosis and fibrinolysis, yet its dynamic changes pre‐ and post‐intravenous thrombolysis (IVT) for predicting brain injury severity and prognosis in acute ischemic stroke (AIS) patients remain unclear.
Wenhai Zhai +28 more
wiley +1 more source
Australian clinical guideline for deprescribing in older people. [PDF]
europepmc +1 more source
Correction: Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings. [PDF]
Gavin KM, Sundermann ML, Wieland A.
europepmc +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
Linking guideline to regular feedback to increase appropriate requests for clinical tests: blood gas analysis in intensive care [PDF]
Merlani Paolo +4 more
openalex +1 more source
Changes in Immune‐Inflammation Status and Acute Ischemic Stroke Prognosis in Prospective Cohort
ABSTRACT Background Inflammation is a critical risk factor for poor outcomes in cerebral infarction. Prior studies focused primarily on baseline inflammation status, neglecting dynamic longitudinal changes. We try to investigate the association between immune‐inflammation status alterations and stroke prognosis, and evaluated three systemic biomarkers'
Songfang Chen +11 more
wiley +1 more source
From Guideline to Lifeline: Turning Status Epilepticus Management Evidence Into Improved Outcomes. [PDF]
Punia V.
europepmc +1 more source
Authors' reply re: Prevention of early‐onset Group B streptococcal disease. Green‐top Guideline No. 36 [PDF]
Rhona Hughes +4 more
openalex +1 more source
Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia
ABSTRACT Background Familial dysautonomia (FD) is a hereditary neurodevelopmental disorder caused by aberrant splicing of the ELP1 gene, leading to a tissue‐specific reduction in ELP1 protein expression. Preclinical models indicate that increasing ELP1 levels can mitigate disease manifestations.
Alejandra González‐Duarte +13 more
wiley +1 more source

